At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 772 enrolled
Drug / intervention
Tildrakizumab 200 mg +2 moredrug
Likely dose
Tildrakizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)
In Brief
A Phase 3 clinical trial evaluating Tildrakizumab 200 mg, Tildrakizumab 100 mg, and 1 other intervention for Plaque Psoriasis. Completed, enrolled 772 participants.
Detailed Summary
This study is being conducted to evaluate the efficacy and safety/tolerability of subcutaneous tildrakizumab (MK-3222), followed by an optional long-term safety extension study, in participants with moderate-to-severe chronic plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartDec 2012
Primary CompletionOct 2015
Study CompletionNov 2021
TodayJul 2026
First PostedNov 6, 2012
Enrollment StartDec 6, 2012
Primary CompletionOct 28, 2015
Study CompletionNov 10, 2021
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 13.7 years ago
Interventions
Tildrakizumab 200 mgdrug
Two tildrakizumab 100 mg/mL pre-filled syringes (PFS)
Tildrakizumab 100 mgdrug
Tildrakizumab 100 mg/mL PFS
Matching Placebodrug
Matching placebo to tildrakizumab PFS